WO2012110253A3 - Exosomal biomarkers for predicting cardiovascular events - Google Patents

Exosomal biomarkers for predicting cardiovascular events Download PDF

Info

Publication number
WO2012110253A3
WO2012110253A3 PCT/EP2012/000714 EP2012000714W WO2012110253A3 WO 2012110253 A3 WO2012110253 A3 WO 2012110253A3 EP 2012000714 W EP2012000714 W EP 2012000714W WO 2012110253 A3 WO2012110253 A3 WO 2012110253A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarker
subject
serpin
fluid
serum
Prior art date
Application number
PCT/EP2012/000714
Other languages
French (fr)
Other versions
WO2012110253A2 (en
Inventor
Dominique De Kleijn
Gerard Pasterkamp
Leonardus Timmers
Siu Kwan Sze
Original Assignee
Cavadis B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/052437 external-priority patent/WO2012110099A1/en
Priority claimed from PCT/EP2011/054567 external-priority patent/WO2012126531A1/en
Application filed by Cavadis B.V. filed Critical Cavadis B.V.
Priority to EP12722288.3A priority Critical patent/EP2676141A2/en
Priority to US13/995,760 priority patent/US20140024046A1/en
Publication of WO2012110253A2 publication Critical patent/WO2012110253A2/en
Publication of WO2012110253A3 publication Critical patent/WO2012110253A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Abstract

The present invention relates to a method of predicting the risk of a subject developing a cardiovascular event, comprising determining the presence of a biomarker that is indicative of the risk of developing a cardiovascular event in an exosome sample from the subject. The exosomes are suitably isolated from a body fluid selected from serum, plasma, blood, urine, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, synovial fluid, breast milk, saliva, in particular serum. Alternatively, the exosomes are present in a body fluid, in particular serum. The biomarker is selected- from the proteins Vitronectin, Serpin F2, CD14, Cystatin C, Plasminogen, Nidogen 2, Serpin Gl or any combination of two or more of these proteins. The invention further relates to a method of diagnosing the occurrence of acute coronary syndrome in a subject, comprising determining the presence of a biomarker that is indicative of the occurrence of acute coronary syndrome in an exosome sample from the subject. In this method the biomarker is selected from Serpin F2, CD14, Cystatin C or combinations thereof.
PCT/EP2012/000714 2011-02-18 2012-02-17 Exosomal biomarkers for cardiovascular events WO2012110253A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP12722288.3A EP2676141A2 (en) 2011-02-18 2012-02-17 Exosomal biomarkers for predicting cardiovascular events
US13/995,760 US20140024046A1 (en) 2011-02-18 2012-02-17 Exosomal Biomarkers for Cardiovasular Events

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/EP2011/052437 WO2012110099A1 (en) 2011-02-18 2011-02-18 Determination of exosomal biomarkers for predicting cardiovascular events
EPPCT/EP2011/052437 2011-02-18
PCT/EP2011/054567 WO2012126531A1 (en) 2011-03-24 2011-03-24 Method for diagnosing acute coronary syndrome (acs)
EPPCT/EP2011/054567 2011-03-24
EP2011061657 2011-07-08
EPPCT/EP2011/061657 2011-07-08

Publications (2)

Publication Number Publication Date
WO2012110253A2 WO2012110253A2 (en) 2012-08-23
WO2012110253A3 true WO2012110253A3 (en) 2013-02-07

Family

ID=46146805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/000714 WO2012110253A2 (en) 2011-02-18 2012-02-17 Exosomal biomarkers for cardiovascular events

Country Status (1)

Country Link
WO (1) WO2012110253A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120995A1 (en) 2012-02-17 2013-08-22 Cavadis B.V. Exosomal biomarker for cardiovascular events in females
PL2972193T3 (en) 2013-03-13 2020-08-24 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
WO2015038065A1 (en) * 2013-09-11 2015-03-19 Nanyang Technological University Plasma microvesicle biomarkers for ischemic stroke
ES2540255B1 (en) * 2013-11-19 2016-05-12 Tomás SEGURA MARTÍN Method of isolation of apoptotic bodies
EP3387444B1 (en) * 2015-12-08 2023-07-05 UMC Utrecht Holding B.V. Extracellular vesicle markers for stable angina and unstable angina
US11193943B2 (en) * 2017-02-06 2021-12-07 Edward Goetzl Endothelial cell derived exosomes and uses thereof
CN113252806B (en) * 2021-03-25 2023-08-29 嘉兴学院 Use of S-adenosyl homocysteine in the preparation of a product for the diagnosis or treatment of Kawasaki disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017444A1 (en) * 1990-05-03 1991-11-14 Blombaeck Birger A METHOD OF DETERMINING QUANTITATIVELY FIBRINOGEN, FIBRONECTIN, α2-ANTIPLASMIN OR A TRANSLUTAMINASE
WO2000065349A2 (en) * 1999-04-28 2000-11-02 Cardiogenics Inc. Method for determining plasminogen activator inhibitor
US20070099242A1 (en) * 2005-10-31 2007-05-03 Heinecke Jay W Lipoprotein-associated markers for cardiovascular disease
WO2009019215A1 (en) * 2007-08-03 2009-02-12 Dkfz Deutsches Krebsforschungszentrum Method for prenatal diagnosis using exosomes and cd24 as a marker
US20100184046A1 (en) * 2008-11-12 2010-07-22 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2010126370A2 (en) * 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017444A1 (en) * 1990-05-03 1991-11-14 Blombaeck Birger A METHOD OF DETERMINING QUANTITATIVELY FIBRINOGEN, FIBRONECTIN, α2-ANTIPLASMIN OR A TRANSLUTAMINASE
WO2000065349A2 (en) * 1999-04-28 2000-11-02 Cardiogenics Inc. Method for determining plasminogen activator inhibitor
US20070099242A1 (en) * 2005-10-31 2007-05-03 Heinecke Jay W Lipoprotein-associated markers for cardiovascular disease
WO2009019215A1 (en) * 2007-08-03 2009-02-12 Dkfz Deutsches Krebsforschungszentrum Method for prenatal diagnosis using exosomes and cd24 as a marker
US20100184046A1 (en) * 2008-11-12 2010-07-22 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2010126370A2 (en) * 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALVAREZ-LLAMAS G. ET AL.: "Recent advances in atherosclerosis-based proteomics: New biomarkers and a future perspective", EXPERT REV. PROTEOMICS, vol. 51, no. 5, October 2008 (2008-10-01), pages 679 - 691, XP008114661 *
BAYÉS-GENIS A. ET AL.: "Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina", THROMB. HAEMOST., vol. 81, no. 6, June 1999 (1999-06-01), pages 865 - 868, XP009164739 *
LAI R C. ET AL.: "Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury", STEM CELL RES., vol. 4, no. 3, May 2010 (2010-05-01), pages 214 - 222, XP027054731 *
ROBBIE L.A. ET AL.: "Inhibitors of fibrinolysis are elevated in atherosclerotic plaque", ARTERIOSCLER. THROMB. VASC. BIOL., vol. 16, no. 4, April 1996 (1996-04-01), pages 539 - 545, XP009164641 *
SIMPSON R.J. ET AL.: "Exosomes: proteomic insights and diagnostic potential", EXPERT REV. PROTEOMICS, vol. 6, no. 3, June 2009 (2009-06-01), pages 267 - 283, XP009125412 *

Also Published As

Publication number Publication date
WO2012110253A2 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
WO2012110253A3 (en) Exosomal biomarkers for predicting cardiovascular events
JP2013516619A5 (en)
Møller et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure
WO2010019553A3 (en) Biomarker detection process and assay of neurological condition
Khoonsari et al. Improved differential diagnosis of Alzheimer’s disease by integrating ELISA and mass spectrometry-based cerebrospinal fluid biomarkers
Noh et al. Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virus-associated hepatocellular carcinoma
EP2829881A3 (en) Diagnostic for colorectal cancer
ATE507720T1 (en) DETECTION OF LYSOPHOSPHATIDYLCHOLINE FOR PROGNOSIS OR DIAGNOSIS OF A SYSTEMIC INFLAMMATORY CONDITION
WO2011035012A3 (en) Methods and compositions for diagnosing heart failure
Ciregia et al. Putative salivary biomarkers useful to differentiate patients with fibromyalgia
Javanmardi et al. Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients: The first experience in Iran
Charro et al. Serum proteomics signature of Cystic Fibrosis patients: A complementary 2-DE and LC–MS/MS approach
Agnello et al. Presepsin and midregional proadrenomedullin in pediatric oncologic patients with febrile neutropenia
El-Sadek et al. Arginine dimethylation products in pediatric patients with chronic kidney disease
WO2013090857A8 (en) Identification of two novel biomarkers for niemann-pick disease type c
PL1977244T3 (en) Distinction between bacterial meningitis and viral meningitis
MX2012003168A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure.
Günebakmaz et al. Increased serum asymmetric dimethylarginine level is an independent predictor of contrast-induced nephropathy
NZ703055A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
FI20085101A0 (en) The method of irritable bowel syndrome IBS diagnosing
DE602006013192D1 (en) DIAGNOSTIC TEST FOR INFLAMMATORY ENDOTHLE ERROR FUNCTIONS IN PREGNANCY
WO2011112397A3 (en) Mrna as biomarkers for liver injury or other liver perturbations
Ortega-Ávila et al. Early atherosclerotic lesions and post-mortem serum cholesterol level in a group of Colombian children
JP2018523134A (en) Prediction of risk of developing disseminated infections in intensive care unit hospitalized patients
Jastrzebska et al. The character of haemostatic disorders and level of protein S-100 in acute ischaemic stroke can affect survival in the first week of follow-up: a pilot study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12722288

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012722288

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13995760

Country of ref document: US